Charcot-Marie-Tooth Disease and Implications on Corneal Refractive Surgery

Majid Moshirfar; Alyson N Tukan; Nour Bundogji; Yasmyne C Ronquillo

doi:10.1007/s40123-022-00524-9

Charcot-Marie-Tooth Disease and Implications on Corneal Refractive Surgery

Ophthalmol Ther. 2022 Aug;11(4):1301-1307. doi: 10.1007/s40123-022-00524-9. Epub 2022 Jun 11.

Authors

Majid Moshirfar^{1

2

3}, Alyson N Tukan⁴, Nour Bundogji⁴, Yasmyne C Ronquillo⁵

Affiliations

¹ Hoopes Vision Research Center, Hoopes Vision, 11820 S. State Street Suite #200, Draper, UT, 84020, USA. cornea2020@me.com.
² John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT, USA. cornea2020@me.com.
³ Utah Lions Eye Bank, Murray, UT, USA. cornea2020@me.com.
⁴ University of Arizona College of Medicine Phoenix, Phoenix, AZ, USA.
⁵ Hoopes Vision Research Center, Hoopes Vision, 11820 S. State Street Suite #200, Draper, UT, 84020, USA.

Abstract

Charcot-Marie-Tooth (CMT) disease is the most common inherited polyneuropathy, with a characteristic phenotype of distal muscle weakness, atrophy, and sensory loss. Variable ocular involvement has been documented in patients with CMT, with optic atrophy as the most frequently reported symptom. Although the Charcot-Marie-Tooth Association has generally deemed laser-assisted in situ keratomileuses (LASIK) a safe option for patients with CMT, reports of corneal refractive surgery are lacking in this patient population. This commentary discusses the current understanding of CMT, including its ocular manifestations, and additional specific testing to consider when evaluating these patients for corneal refractive surgery.

Keywords: Charcot–Marie–Tooth disease; LASIK; Optic atrophy; PRK; Polyneuropathy.